Psychedelics as Novel Therapeutics in Alzheimer's Disease: Rationale and Potential Mechanisms.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and clinical rationale without systematic review methodology or new empirical data.
PubMed 34734390 · doi:10.1007/7854_2021_267
What was done
This narrative review synthesized preclinical and clinical literature regarding serotonin 2A receptor (5-HT2AR) agonist classic psychedelics, evaluating their proposed biological mechanisms (such as neuroplasticity, anti-inflammatory actions, and altered functional connectivity) and potential therapeutic utility for Alzheimer's disease (AD) pathophysiology and neuropsychiatric symptoms.
What was found
The abstract reports no quantitative data or specific numerical results. The authors describe preclinical findings indicating that 5-HT2AR agonists modulate learning and memory and may slow or reverse brain atrophy and AD progression. They also note human clinical evidence showing long-lasting anxiolytic and antidepressant effects following single psychedelic doses, suggesting potential benefit for mood and anxiety symptoms in early-stage AD.
Why it matters
It outlines a biological and clinical rationale for investigating psychedelics as multi-target candidates addressing both neurodegeneration and comorbid mood symptoms in Alzheimer's disease.
Limits
As an unsystematic narrative review, the paper provides theoretical reasoning rather than direct clinical trial evidence in patients with Alzheimer's disease. The abstract provides no quantitative metrics, effect sizes, study counts, or clinical safety assessments in dementia populations.
Cited by
- context Psilocybin has not worked well for Alzheimer's disease because patients cannot remember their experience or trip.